1. Home
  2. BLNK vs FHTX Comparison

BLNK vs FHTX Comparison

Compare BLNK & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.69

Market Cap

89.3M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$5.41

Market Cap

247.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
FHTX
Founded
2009
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
89.3M
247.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
FHTX
Price
$0.69
$5.41
Analyst Decision
Buy
Strong Buy
Analyst Count
7
7
Target Price
$2.13
$11.43
AVG Volume (30 Days)
7.6M
157.8K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,631,000.00
$24,518,000.00
Revenue This Year
N/A
$40.89
Revenue Next Year
$17.87
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$2.95
52 Week High
$2.65
$6.79

Technical Indicators

Market Signals
Indicator
BLNK
FHTX
Relative Strength Index (RSI) 23.85 62.02
Support Level $0.77 $5.25
Resistance Level $0.85 $5.95
Average True Range (ATR) 0.07 0.33
MACD -0.01 0.11
Stochastic Oscillator 3.47 68.11

Price Performance

Historical Comparison
BLNK
FHTX

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: